Deal Library / Pharma BD Deal Intelligence

Pharma Deals of 2018

The Pharma Closeout tracks 43 deals, $190.6B in disclosed deal value, 40 with a post-close Outcome Score for the year 2018.

Median Critic Score: 75  ·  Median Outcome Score: 52

Best outcome: Novartis AG / Endocyte, Inc. (96)  ·  Weakest outcome: Takeda Pharmaceutical Company Ltd. / Shire plc (8)

All 43 deals

• Novartis AG / Endocyte, Inc. — 2018 · $2.1B · Worked — the deal delivered on its rationale.
• Servier / Shire plc (Oncology Business) — 2018 · $2.4B · Worked — the deal delivered on its rationale.
• Roche Holding AG / Foundation Medicine, Inc. — 2018 · $5.3B · Worked — the deal delivered on its rationale.
• Merck & Co. Inc. / Eisai Co., Ltd. — 2018 · $5.8B · Worked — the deal delivered on its rationale.
• Swedish Orphan Biovitrum AB / AstraZeneca PLC (Synagis US rights) — 2018 · $2.3B · Worked — the deal delivered on its rationale.
• GlaxoSmithKline plc / Tesaro Inc. — 2018 · $5.1B · Worked — the deal delivered on its rationale.
• Boston Scientific Corporation / BTG plc — 2018 · $4.2B · Worked — the deal delivered on its rationale.
• GSK plc / Pfizer Inc. — 2018 · $0.0M · Worked — the deal delivered on its rationale.
• GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) — 2018 · $12.7B · Worked — the deal delivered on its rationale.
• GlaxoSmithKline plc / Novartis Consumer Healthcare JV — 2018 · $13.0B · Largely worked — most objectives met.
• Sanofi SA / Translate Bio Inc. — 2018 · $805M · Largely worked — most objectives met.
• Celgene Corporation / Juno Therapeutics Inc. — 2018 · $9.0B · Largely worked — most objectives met.
• Novartis AG / AveXis Inc. — 2018 · $8.7B · Largely worked — most objectives met.
• Sanofi SA / Ablynx NV — 2018 · $4.8B · Largely worked — most objectives met.
• Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. — 2018 · $1.2B · Largely worked — most objectives met.
• Orchard Therapeutics Limited / GlaxoSmithKline plc — 2018 · Largely worked — most objectives met.
• Pfizer Inc. / BioNTech SE — 2018 · $425M · Mixed — partial payoff, real shortfalls.
• Sanofi SA / Bioverativ Inc. — 2018 · $11.6B · Mixed — partial payoff, real shortfalls.
• AstraZeneca PLC / Innate Pharma SA — 2018 · $1.3B · Mixed — partial payoff, real shortfalls.
• Celgene Corporation / Impact Biomedicines — 2018 · $7.0B · Mixed — partial payoff, real shortfalls.
• Roche Holding AG / Flatiron Health — 2018 · $1.9B · Mixed — partial payoff, real shortfalls.
• Al Sirona (Luxembourg) Acquisition / Zentiva Group — 2018 · $2.4B · Mixed — partial payoff, real shortfalls.
• Dr. Max / Sensiblu — 2018 · $415M · Mixed — partial payoff, real shortfalls.
• Akebia Therapeutics, Inc. / Keryx Biopharmaceuticals, Inc. — 2018 · $1.3B · Underwhelmed — fell short of the thesis.
• Mylan N.V. / Novartis AG (TOBI franchise) — 2018 · $463M · Underwhelmed — fell short of the thesis.
• GSK plc / 23andMe, Inc. — 2018 · $300M · Underwhelmed — fell short of the thesis.
• GlaxoSmithKline plc / 23andMe, Inc. — 2018 · $300M · Underwhelmed — fell short of the thesis.
• Eli Lilly and Company / Sigilon Therapeutics Inc. — 2018 · $1.8B · Underwhelmed — fell short of the thesis.
• Mereo BioPharma Group plc / OncoMed Pharmaceuticals, Inc. — 2018 · $57M · Did not work — the deal failed to deliver.
• Akcea Therapeutics, Inc. / Ionis Pharmaceuticals, Inc. — 2018 · $1.7B · Did not work — the deal failed to deliver.
• Roche Holding AG / Tusk Therapeutics — 2018 · $759M · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Nektar Therapeutics — 2018 · $3.6B · Did not work — the deal failed to deliver.
• Astellas Pharma Inc. / Mitobridge, Inc. — 2018 · $450M · Did not work — the deal failed to deliver.
• Takeda Pharmaceutical Company Ltd. / Wave Life Sciences Ltd. — 2018 · $2.0B · Did not work — the deal failed to deliver.
• Alexion Pharmaceuticals, Inc. / Wilson Therapeutics AB — 2018 · $855M · Did not work — the deal failed to deliver.
• Eli Lilly and Company / ARMO BioSciences Inc. — 2018 · $1.6B · Did not work — the deal failed to deliver.
• H. Lundbeck A/S / Prexton Therapeutics BV — 2018 · $1.1B · Did not work — the deal failed to deliver.
• Alexion Pharmaceuticals, Inc. / Syntimmune, Inc. — 2018 · $1.2B · Did not work — the deal failed to deliver.
• Takeda Pharmaceutical Company Ltd. / TiGenix NV — 2018 · $640M · Did not work — the deal failed to deliver.
• Takeda Pharmaceutical Company Ltd. / Shire plc — 2018 · $62.0B · Did not work — the deal failed to deliver.
• Pieris Pharmaceuticals, Inc. / Seattle Genetics, Inc. — 2018 · $1.2B
• Genentech, Inc. (Roche Holding AG) / Affimed N.V. — 2018 · $5.1B
• Janssen (Cilag GmbH International, J&J) / argenx SE — 2018 · $1.8B

← Deal Library  ·  Interactive search  ·  How we score deals